Article
Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has…
Ceased publishing: Oncolytic Virotherapy · 2015 · Dunlap KM, Bartee MY, Bartee E
Key facts
| Title | Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor–resistant multiple myeloma |
|---|---|
| First author | Dunlap KM, Bartee MY, Bartee E |
| Journal | Ceased publishing: Oncolytic Virotherapy |
| Published | Jan 13, 2015 |
| DOI | 10.2147/OV.S72372 |
| Devices mentioned | BK110039, K103302, K850512, K850513 |
| Product codes mentioned | JJH, KIP, KIT, NDS, NJT, OOI, PCA |
At a glance
- 1–9 FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1